Best-in-class testing, with the most comprehensive results

Dr. Jyotsna Shah is the President and Laboratory Director of IGeneX Clinical Laboratory, Palo Alto, CA. Dr. Jyotsna Shah is the President and Laboratory Director of IGeneX Clinical Laboratory, Palo Alto, CA. Dr. Shah has over 40 years of research experience in immunology, molecular biology and microbiology, has been published and holds more than 20 patents. After receiving her B.Sc. and M.Sc in Biological Sciences from UK and her Ph.D. in diagnostic immunology from Nairobi University in Kenya, Dr. Shah joined International Laboratory for Research on Animal Diseases (ILRAD) as a post-doctoral scientist and started the first DNA sequencing laboratory in E. Africa. On completion of her fellowship, she went on to join Harvard University’s Department of Tropical Medicine as a research fellow and continued work on development of molecular tools for diagnosis of parasitic diseases. Since then Dr. Shah has worked at several Biotechnology companies focusing on the development of novel molecular technologies for diagnosis of infectious diseases and has become a world expert on use of Fluorescent in Situ Hybridization (FISH) technique for direct detection of pathogens in clinical samples. Dr. Shah joined IGeneX as the Director of Research and Development in 1997 and in 2003 became Laboratory Director (clinical and research). During her time with IGenex she introduced the first Fluorescent In Situ Hybridization (FISH) test for Babesia and also set up the PCR department for tick-borne diseases. Under Dr. Shah’s direction, the laboratory has developed an excellent QA program and her scientific guidance, IGeneX has become the world’s leading reference laboratory for diagnosis of tick-borne diseases After receiving her B.Sc. and M.Sc in Biological Sciences from UK and her Ph.D. in diagnostic immunology from Nairobi University in Kenya, Dr. Shah joined International Laboratory for Research on Animal Diseases (ILRAD) as a post-doctoral scientist and started the first DNA sequencing laboratory in E. Africa. On completion of her fellowship, she went on to join Harvard University’s Department of Tropical Medicine as a research fellow and continued work on development of molecular tools for diagnosis of parasitic diseases.

Tom Paskert has been the head of Finance for IGeneX since 2016. Prior to IGeneX, Tom worked at both large multi-national corporations as well as several smaller startups where he led funding efforts, which raised in excess of $250M. He has extensive experience growing organizations and installing infrastructures and has been involved with many mergers and acquisitions.

Brenda Shiplett has worked at IGeneX from its start in December 1991 and is the Vice President of Administration. Brenda worked with the former CEO at Allergenetics, Dr. Nick Harris, for years in the Clinical Studies and the Customer Service departments. After Allergenetics was purchased by 3M Corporation, she worked along side Dr. Harris in the Technical Services Department and as Marketing Communications Coordinator. When the Laboratory was sold by 3M Corporation, she assisted Dr. Harris in building IGeneX from the small laboratory of seven employees 25 years ago, to the exceptional laboratory that it is today.

Iris Cruz has an extensive background in operations, quality, and compliance. She joined IGeneX as a clinical scientist in 1992 and currently serves as the Clinical Laboratory Manager. Iris has a record of accomplishment installing and managing state-of-the art systems and quality control processes at IGeneX. She also provides significant leadership and coordination for the large numbers of clinical tests and validation studies performed by IGeneX.

Robert Giguere has been the Director of Sales at IGeneX since 1996. Robert has spent the majority of his career dealing with clinical laboratory medicine in the fields of genetics, endocrinology, and immunology. He did his undergraduate study at Providence College and then got his molecular biology training at MIT. He started his laboratory career at Nichols Institute in California and has held executive positions at a number of nationally recognized clinical laboratories. These include the molecular laboratory, Collaborative Research, and Repomedix in greater Boston. Prior to IGeneX, Robert was COO and Sr. VP at Boston BioMedical Clinical Laboratory.